379 related articles for article (PubMed ID: 31500572)
21. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
Conradie F; Bagdasaryan TR; Borisov S; Howell P; Mikiashvili L; Ngubane N; Samoilova A; Skornykova S; Tudor E; Variava E; Yablonskiy P; Everitt D; Wills GH; Sun E; Olugbosi M; Egizi E; Li M; Holsta A; Timm J; Bateson A; Crook AM; Fabiane SM; Hunt R; McHugh TD; Tweed CD; Foraida S; Mendel CM; Spigelman M;
N Engl J Med; 2022 Sep; 387(9):810-823. PubMed ID: 36053506
[TBL] [Abstract][Full Text] [Related]
22. The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis.
Hasan T; Medcalf E; Nyang'wa BT; Egizi E; Berry C; Dodd M; Foraida S; Gegia M; Li M; Mirzayev F; Morgan H; Motta I; Nguyen L; Schumacher S; Schlub T; Fox G
Clin Infect Dis; 2024 Mar; 78(3):730-741. PubMed ID: 37874021
[TBL] [Abstract][Full Text] [Related]
23. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
Centers for Disease Control and Prevention
MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
[TBL] [Abstract][Full Text] [Related]
24. Development of new drug-regimens against multidrug-resistant tuberculosis.
Vasava MS; Nair SG; Rathwa SK; Patel DB; Patel HD
Indian J Tuberc; 2019 Jan; 66(1):12-19. PubMed ID: 30797268
[TBL] [Abstract][Full Text] [Related]
25. Mycobactericidal Effects of Different Regimens Measured by Molecular Bacterial Load Assay among People Treated for Multidrug-Resistant Tuberculosis in Tanzania.
Mbelele PM; Mpolya EA; Sauli E; Mtafya B; Ntinginya NE; Addo KK; Kreppel K; Mfinanga S; Phillips PPJ; Gillespie SH; Heysell SK; Sabiiti W; Mpagama SG
J Clin Microbiol; 2021 Mar; 59(4):. PubMed ID: 33536294
[TBL] [Abstract][Full Text] [Related]
26. Long-term impact of the adoption of bedaquiline-containing regimens on the burden of drug-resistant tuberculosis in China.
Agnarson AM; Wang XC; Potluri R; Bhandari H; Dhir A; Kambili C; Metz L
BMC Infect Dis; 2020 Feb; 20(1):113. PubMed ID: 32041542
[TBL] [Abstract][Full Text] [Related]
27. Pretomanid for tuberculosis: a systematic review.
Gils T; Lynen L; de Jong BC; Van Deun A; Decroo T
Clin Microbiol Infect; 2022 Jan; 28(1):31-42. PubMed ID: 34400340
[TBL] [Abstract][Full Text] [Related]
28. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
Diacon AH; Dawson R; von Groote-Bidlingmaier F; Symons G; Venter A; Donald PR; van Niekerk C; Everitt D; Hutchings J; Burger DA; Schall R; Mendel CM
Am J Respir Crit Care Med; 2015 Apr; 191(8):943-53. PubMed ID: 25622149
[TBL] [Abstract][Full Text] [Related]
29. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.
Guglielmetti L; Ardizzoni E; Atger M; Baudin E; Berikova E; Bonnet M; Chang E; Cloez S; Coit JM; Cox V; de Jong BC; Delifer C; Do JM; Tozzi DDS; Ducher V; Ferlazzo G; Gouillou M; Khan A; Khan U; Lachenal N; LaHood AN; Lecca L; Mazmanian M; McIlleron H; Moschioni M; O'Brien K; Okunbor O; Oyewusi L; Panda S; Patil SB; Phillips PPJ; Pichon L; Rupasinghe P; Rich ML; Saluhuddin N; Seung KJ; Tamirat M; Trippa L; Cellamare M; Velásquez GE; Wasserman S; Zimetbaum PJ; Varaine F; Mitnick CD
Trials; 2021 Sep; 22(1):651. PubMed ID: 34563240
[TBL] [Abstract][Full Text] [Related]
30. Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis.
Ryckman TS; Schumacher SG; Lienhardt C; Sweeney S; Dowdy DW; Mirzayev F; Kendall EA
Lancet Glob Health; 2024 Jun; 12(6):e995-e1004. PubMed ID: 38762299
[TBL] [Abstract][Full Text] [Related]
31. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.
Espinal MA; Kim SJ; Suarez PG; Kam KM; Khomenko AG; Migliori GB; Baéz J; Kochi A; Dye C; Raviglione MC
JAMA; 2000 May; 283(19):2537-45. PubMed ID: 10815117
[TBL] [Abstract][Full Text] [Related]
32. Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective.
Kendall EA; Cohen T; Mitnick CD; Dowdy DW
Int J Infect Dis; 2017 Mar; 56():185-189. PubMed ID: 28007660
[TBL] [Abstract][Full Text] [Related]
33. An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study).
Esmail A; Oelofse S; Lombard C; Perumal R; Mbuthini L; Goolam Mahomed A; Variava E; Black J; Oluboyo P; Gwentshu N; Ngam E; Ackerman T; Marais L; Mottay L; Meier S; Pooran A; Tomasicchio M; Te Riele J; Derendinger B; Ndjeka N; Maartens G; Warren R; Martinson N; Dheda K
Am J Respir Crit Care Med; 2022 May; 205(10):1214-1227. PubMed ID: 35175905
[No Abstract] [Full Text] [Related]
34. Principles of chemotherapy for tuberculosis in national tuberculosis programmes of low- and middle-income countries.
Chiang CY; Lin CJ
Indian J Tuberc; 2020 Dec; 67(4S):S16-S22. PubMed ID: 33308663
[TBL] [Abstract][Full Text] [Related]
35. Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings.
Sotgiu G; Tiberi S; Centis R; D'Ambrosio L; Fuentes Z; Zumla A; Migliori GB
Int J Infect Dis; 2017 Mar; 56():190-193. PubMed ID: 27816662
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
Wirth D; Dass R; Hettle R
BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
[TBL] [Abstract][Full Text] [Related]
37. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study.
Schnippel K; Berhanu RH; Black A; Firnhaber C; Maitisa N; Evans D; Sinanovic E
BMC Infect Dis; 2016 Oct; 16(1):593. PubMed ID: 27769174
[TBL] [Abstract][Full Text] [Related]
38. Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness.
Nsengiyumva NP; Campbell JR; Oxlade O; Vesga JF; Lienhardt C; Trajman A; Falzon D; Den Boon S; Arinaminpathy N; Schwartzman K
PLoS Med; 2022 Jun; 19(6):e1004032. PubMed ID: 35696431
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.
Wolfson LJ; Gibbert J; Wirth D; Diel R
Eur Respir J; 2015 Dec; 46(6):1826-9. PubMed ID: 26493796
[No Abstract] [Full Text] [Related]
40. Pretomanid: First Approval.
Keam SJ
Drugs; 2019 Nov; 79(16):1797-1803. PubMed ID: 31583606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
